A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment with
To assess the efficacy of seltorexant 20 mg as monotherapy compared with placebo in improving depressive symptoms in participants with MDDIS
Study phase: III
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
Adults 18-74 diagnosed with MDD with a current episode with at least a 2 week duration
Primary disease category: Mental Health
This study is enrolling healthy volunteers.
Sponsor: Janssen
Protocol number: 42847922MDD3011
Projected enrollment dates: August 2026 to November 2027
Official study title: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment with Seltorexant